ST. LOUIS—July 14, 2008--GenoMed (OTC Pink Sheets GMED), the Public Health Company™, announced that its CEO, David Moskowitz MD, has been selected to chair a session on biomarkers in drug development at IBC’s Drug Discovery & Development of Innovative Therapeutics (DDT) Conference in Boston. IBC’s DDT Conference will be held August 4-7, 2008 (http://www.drugdisc.com/). Dr. Moskowitz will chair a session on Translational Medicine. The conference will include leaders from academia as well as the biotech and pharmaceutical industries.
Said Dr. David Moskowitz, GenoMed’s CEO, “It’s of course a great honor for me to be asked to chair a session on biomarkers in drug development. The cancer biomarkers we’ve found, called SNPs, operate at the very beginning of tumor formation. The genes identified by our SNPs should therefore make ideal targets for new treatments. Plus, genomic biomarkers are the only way to tell somebody’s medical fortune in advance of the disease. A patient at high risk for ovarian cancer, for example, could get a pelvic ultrasound every year. The goal would be early detection of the cancer while it’s still small and can be removed surgically for a cure. I want to improve cancer mortality within the next couple of years.”
Dr. Moskowitz continued by saying, “Exposure at this conference will be helpful because we’re currently building a peer-reviewed virtuous virtual pharmaceutical company™. It’s ‘virtuous’ because we’ll use cocktails of existing drugs first, before designing any new drugs. Drug combinations are patentable, and existing drugs are safer than new ones. This approach should allow us to come to market much sooner and for a much lower cost than designing a new drug, which currently costs $1 billion and takes 12 years. Patients with cancer don’t have 12 years to wait.”
Dr. Moskowitz ended by saying, “Our SNP biomarkers are the best in the industry, and should guarantee efficacy of the drugs we come up with. We have several thousand target genes for each cancer, so that we can afford to throw out 99.9%, the usual attrition rate because of drug toxicity, and still be left with a few drugs good enough for FDA approval. By taking most of the risk out of drug discovery, we should make it more attractive to financial institutions aware of Big Pharma’s dry pipeline but worried by biotech’s high failure rate.”
About GenoMed
GenoMed is a leader in biomarker discovery. GenoMed has found over 5,000 single nucleotide polymorphisms or SNPs (pronounced “snips”) for each of 6 common cancers in whites: breast, colon, lung, ovary, pancreas, and prostate. GenoMed can already recommend cocktails of existing, non-toxic drugs for each of these tumors, an approach called “kind chemotherapy.” GenoMed is looking for patients with metastatic cancer for “compassionate use” clinical trials testing the validity of this new approach to cancer, the first in 50 years.
The company also hopes to have an FDA-approved cancer Healtchip® to detect patients at high risk for these cancers within a few years.
Anybody interested should contact Dr. Moskowitz at dwmoskowitz@genomed.com.
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company’s) treatments. The words or phrases “ought to,” “should,” “could,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Contact:
David W. Moskowitz MD
CEO, GenoMed
tel. 314.983.9933
dwmoskowitz@genomed.com
